{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:04:34Z","timestamp":1774418674220,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of neoadjuvant chemotherapy (NACT) before radical hysterectomy (RH) in cervical cancer remains unclear. We evaluated stage-specific outcomes of NACT-RH at a high-volume center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with non-metastatic cT1b1\u20132b cervical cancer who underwent RH between 2013 and 2022. For cT1b cases, prognostic outcomes were compared between patients with cT1b3 (any N) who underwent NACT-RH (High-risk, NACT(+)) and those with cT1b1\u20131b2 N0 who underwent primary RH (Low-risk, NACT(\u2212)), using propensity score matching. For cT2 cases, NACT-RH versus primary RH was compared using inverse probability weighting to adjust for baseline differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 191 patients who underwent RH (cT1:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200999; cT2:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200992), the matched cT1 cohort comprised 15 High-risk, NACT(+) and 30 Low-risk, NACT(\u2212) patients. Five-year progression-free survival (PFS) was 75.0% (95% confidence interval [CI], 53.4\u2013100.0%) versus 89.9% (95% CI, 79.6\u2013100.0%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.427). Overall survival (OS) was 100% in both groups with a median follow-up of\u2009&gt;\u200970\u00a0months. In cT2, NACT-RH (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200973) versus primary RH (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919) showed hazard ratios of 2.88 for PFS (95% CI, 0.69\u201311.97) and 5.64 for OS (95% CI, 0.70\u201345.35) after baseline adjustment. Among cT2 patients who underwent NACT-RH, PFS and OS were worse in those without an objective response to NACT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918, all cT2b) than in responders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NACT-RH was associated with encouraging long-term outcomes in cT1b3, whereas outcomes in cT2 cases remain uncertain, supporting careful selection and response-adapted strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-02998-0","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:45:09Z","timestamp":1772624709000},"page":"762-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of neoadjuvant chemotherapy followed by radical hysterectomy in cervical cancer: a single-center study"],"prefix":"10.1007","volume":"31","author":[{"given":"Akitoshi","family":"Yamamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-1834","authenticated-orcid":false,"given":"Masayo","family":"Ukita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinako","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Airi","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Kanbayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"2","key":"2998_CR1","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V et al (2023) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 11(2):e197-206. https:\/\/doi.org\/10.1016\/S2214-109X(22)00501-0","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2998_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2007.08.076","volume":"1","author":"S Fujii","year":"2007","unstructured":"Fujii S, Takakura K, Matsumura N et al (2007) Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol 1(1):4\u201313. https:\/\/doi.org\/10.1016\/j.ygyno.2007.08.076","journal-title":"Gynecol Oncol"},{"issue":"Suppl 2","key":"2998_CR3","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1055\/s-0041-1736176","volume":"12","author":"I Konishi","year":"2021","unstructured":"Konishi I (2021) The Okabayashi radical hysterectomy: basic principle and step-by-step procedure. Surg J (N Y) 12(Suppl 2):S57-69. https:\/\/doi.org\/10.1055\/s-0041-1736176","journal-title":"Surg J (N Y)"},{"issue":"8","key":"2998_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/ijgc-2020-001387","volume":"30","author":"N Sakuragi","year":"2020","unstructured":"Sakuragi N, Kaneuchi M, Kato T et al (2020) Tailored radical hysterectomy for locally advanced cervical cancer. Int J Gynecol Cancer 30(8):1136\u20131142. https:\/\/doi.org\/10.1136\/ijgc-2020-001387","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"2998_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IGC.0000000000000202","volume":"24","author":"M Mikami","year":"2014","unstructured":"Mikami M, Aoki Y, Sakamoto M et al (2014) Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: a survey of the Japanese Gynecologic Oncology Group. Int J Gynecol Cancer 24(7):1333\u20131340. https:\/\/doi.org\/10.1097\/IGC.0000000000000202","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2998_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jog.12896","volume":"42","author":"YH Peng","year":"2016","unstructured":"Peng YH, Wang XX, Zhu JS et al (2016) Neo-adjuvant chemotherapy plus surgery versus surgery alone for cervical cancer: meta-analysis of randomized controlled trials. J Obstet Gynaecol Res 42(2):128\u2013135. https:\/\/doi.org\/10.1111\/jog.12896","journal-title":"J Obstet Gynaecol Res"},{"key":"2998_CR7","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.2147\/OTT.S186451","volume":"7","author":"H Zhao","year":"2019","unstructured":"Zhao H, He Y, Yang SL et al (2019) Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis. Onco Targets Ther 7:1881\u20131891. https:\/\/doi.org\/10.2147\/OTT.S186451","journal-title":"Onco Targets Ther"},{"issue":"10","key":"2998_CR8","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/bjc.2013.179","volume":"28","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yoshikawa H, Kobayashi H et al (2013) Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 28(10):1957\u20131963. https:\/\/doi.org\/10.1038\/bjc.2013.179","journal-title":"Br J Cancer"},{"key":"2998_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101945","volume":"1","author":"C Marchetti","year":"2020","unstructured":"Marchetti C, Fagotti A, Tombolini V et al (2020) Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treat Rev 1:101945. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101945","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2998_CR10","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","volume":"21","author":"NR Abu-Rustum","year":"2023","unstructured":"Abu-Rustum NR, Yashar CM, Arend R et al (2023) NCCN guidelines\u00ae insights: cervical cancer, version 1.2024. J Natl Compr Canc Netw 21(12):1224\u20131233. https:\/\/doi.org\/10.6004\/jnccn.2023.0062","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2998_CR11","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e15","volume":"35","author":"M Seino","year":"2024","unstructured":"Seino M, Nagase S, Tokunaga H et al (2024) Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. J Gynecol Oncol 35(1):e15. https:\/\/doi.org\/10.3802\/jgo.2024.35.e15","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"2998_CR12","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e23","volume":"29","author":"M Mikami","year":"2018","unstructured":"Mikami M, Shida M, Shibata T et al (2018) Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer. J Gynecol Oncol 29(2):e23. https:\/\/doi.org\/10.3802\/jgo.2018.29.e23","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"2998_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/AOG.0000000000003280","volume":"133","author":"K Matsuo","year":"2019","unstructured":"Matsuo K, Shimada M, Yamaguchi S et al (2019) Association of radical hysterectomy surgical volume and survival for early-stage cervical cancer. Obstet Gynecol 133(6):1086\u20131098. https:\/\/doi.org\/10.1097\/AOG.0000000000003280","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2998_CR14","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e29","volume":"27","author":"Y Ikeda","year":"2016","unstructured":"Ikeda Y, Furusawa A, Kitagawa R et al (2016) Practice patterns of adjuvant therapy for intermediate\/high recurrence risk cervical cancer patients in Japan. J Gynecol Oncol 27(3):e29. https:\/\/doi.org\/10.3802\/jgo.2016.27.e29","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"2998_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/ijgc-2020-002344","volume":"31","author":"A Furusawa","year":"2021","unstructured":"Furusawa A, Takekuma M, Mori K et al (2021) A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082). Int J Gynecol Cancer 31(4):623\u2013626. https:\/\/doi.org\/10.1136\/ijgc-2020-002344","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2998_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ygyno.2015.06.027","volume":"141","author":"Z Yang","year":"2016","unstructured":"Yang Z, Chen D, Zhang J et al (2016) The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: a randomized multicenter study. Gynecol Oncol 141(2):231\u2013239. https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.027","journal-title":"Gynecol Oncol"},{"issue":"16","key":"2998_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2017.75.9985","volume":"36","author":"S Gupta","year":"2018","unstructured":"Gupta S, Maheshwari A, Parab P et al (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36(16):1\u201355. https:\/\/doi.org\/10.1200\/JCO.2017.75.9985","journal-title":"J Clin Oncol"},{"issue":"1","key":"2998_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07672-w","volume":"20","author":"M Takekuma","year":"2020","unstructured":"Takekuma M, Takahashi F, Mabuchi S et al (2020) Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy\/concurrent chemoradiotherapy. BMC Cancer 20(1):1169. https:\/\/doi.org\/10.1186\/s12885-020-07672-w","journal-title":"BMC Cancer"},{"issue":"5","key":"2998_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10147-017-1134-x","volume":"22","author":"S Mabuchi","year":"2017","unstructured":"Mabuchi S, Matsumoto Y, Komura N et al (2017) The efficacy of surgical treatment of recurrent or persistent cervical cancer that develops in a previously irradiated field: a monoinstitutional experience. Int J Clin Oncol 22(5):927\u2013936. https:\/\/doi.org\/10.1007\/s10147-017-1134-x","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"2998_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","volume":"22","author":"PJ Eifel","year":"2004","unstructured":"Eifel PJ, Winter K, Morris M et al (2004) Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22(5):872\u2013880. https:\/\/doi.org\/10.1200\/JCO.2004.07.197","journal-title":"J Clin Oncol"},{"issue":"5","key":"2998_CR21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/0360-3016(94)00613-P","volume":"32","author":"M Werner-Wasik","year":"1995","unstructured":"Werner-Wasik M, Schmid CH, Bornstein L et al (1995) Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma. Int J Radiat Oncol Biol Phys 32(5):1309\u20131317. https:\/\/doi.org\/10.1016\/0360-3016(94)00613-P","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10434","key":"2998_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K et al (2024) Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 403(10434):1341\u20131350. https:\/\/doi.org\/10.1016\/S0140-6736(24)00317-9","journal-title":"Lancet"},{"issue":"1","key":"2998_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","volume":"25","author":"K Li","year":"2024","unstructured":"Li K, Chen J, Hu Y et al (2024) Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol 25(1):76\u201385. https:\/\/doi.org\/10.1016\/S1470-2045(23)00531-4","journal-title":"Lancet Oncol"},{"key":"2998_CR24","doi-asserted-by":"publisher","first-page":"10469","DOI":"10.2147\/CMAR.S270258","volume":"12","author":"Y Huang","year":"2020","unstructured":"Huang Y, Liu L, Cai J et al (2020) The efficacy and response predictors of platinum-based neoadjuvant chemotherapy in locally advanced cervical cancer. Cancer Manag Res 12:10469\u201310477. https:\/\/doi.org\/10.2147\/CMAR.S270258","journal-title":"Cancer Manag Res"},{"issue":"3","key":"2998_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1006\/gyno.1995.1164","volume":"57","author":"GL Eddy","year":"1995","unstructured":"Eddy GL, Manetta A, Alvarez RD et al (1995) Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol 57(3):412\u2013416. https:\/\/doi.org\/10.1006\/gyno.1995.1164","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2998_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/IGJ.0b013e318197f8be","volume":"19","author":"KD Ki","year":"2009","unstructured":"Ki KD, Song DH, Tong SY et al (2009) Neoadjuvant chemotherapy in bulky stage IB-IIA cervical cancer: results of a quick course with vincristine, bleomycin, and cisplatin. Int J Gynecol Cancer 19(1):50\u201353. https:\/\/doi.org\/10.1111\/IGJ.0b013e318197f8be","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02998-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02998-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02998-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:13:05Z","timestamp":1774415585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02998-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02998-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional ethics committee (SGHIRB#2025010).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}